Lammlundqvist0128
The psychological imagination permeates the expression of mindfulness as a solution to social ills and symbolises the comparative decline of assumptions implicit in Mills' 20th century rousing call to social scientists. © 2020 The Authors. Sociology of Health & Illness published by John Wiley & Sons Ltd on behalf of Foundation for SHIL (SHIL).OBJECTIVES Crohn disease (CD) is a chronic inflammation in the digestive tract that affects millions of Americans. Bowel vascularity has important diagnostic information because inflammation is associated with blood flow changes. We recently developed an ultrasensitive ultrasound microvessel imaging (UMI) technique with high vessel sensitivity. This study aimed to evaluate the feasibility of UMI to assist CD detection and staging. METHODS Ultrasound microvessel imaging was performed on 76 bowel wall segments from 48 symptomatic patients with CD. Clinically indicated computed tomographic/magnetic resonance enterography was used as the reference standard. The vessel-length ratio (VLR, the number of vessel pixels in the bowel wall segment normalized to the segment length) was derived in both conventional color flow imaging (CFI) and UMI to quantitatively stage disease activity. Receiver operating characteristic curves were then analyzed between different disease groups. RESULTS The VLR-CFI and VLR-UMI detected sPhotostable and near-infrared (NIR)-emitting organic fluorophores with large Stokes shifts are in great demand for long-term bioimaging at deeper depths with minimal autofluorescence and self-quenching. We report a new class of benzorhodamines and their analogues that are photostable and emit in the NIR region (up to 785 nm) with large Stokes shifts (>120 nm). The synthesis involves condensation of 7-alkylamino-2-naphthols with 2-(4-(dimethylamino)-2-hydroxybenzoyl)benzoic acid, which leads to bent-shape benzorhodamines that emit orange fluorescence (~600 nm); however, introduction of steric hindrance near the condensation site switches the regioselectivity, providing a linear benzorhodamine system for the first time. The linear benzorhodamine derivatives provide bright fluorescence images in cell as well as in tissue. A carboxy benzorhodamine is applied for photothermal therapy of cancer cells as well as xenograft cancer mice. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.Bismuth(III) flavonolates the impact of structural diversity on antibacterial activity, mammalian cell viability, and cellular uptake. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.The Functional Movement Screen (FMS) and physical performance testing are often suggested to be related to sports injury risk. This study explored if the combination of FMS and physical performance testing improved identification of non-contact injury risk over FMS testing alone in an elite junior Australian football cohort. Over a three-year period, 573 players completed pre-season injury history questionnaires, FMS, physical performance testing (20-m sprint, vertical jump, planned agility testing, and shuttle run test), and subsequent in-season injury surveillance. Results Neither previous injury or FMS score less then 14 were related to an increased risk of subsequent injury in isolation. The combination of FMS composite score ≤14 and previous injury moderately increased the risk of injury [Hazard ratio (HR)= 2.22 (1.09-4.54)]. None of the physical performance measures improved the ability to predict injuries based on FMS composite score. FMS asymmetry was only associated with injury when combined with previous injury and vertical jump performance. Players with ≥1 FMS asymmetry and history of previous injury experienced a large increase in injury risk when vertical jump was poor [HR= 4.26 (1.35-13.42)] or good [HR= 3.17 (1.08-9.29)]. Players with a combination of a good vertical jump, no previous injury, and no FMS asymmetries were also at moderately increased risk of injury [HR= 3.41 (1.11-10.42)]. No physical performance tests improved the ability to identify non-contact injury risk using an FMS composite score threshold. However, a U-shaped relationship between vertical jump and injury risk was identified with both poor and good vertical jump height associated with a moderate-large increase in non-contact injury risk in the presence of ≥1 asymmetrical FMS sub-test. This article is protected by copyright. All rights reserved.Although research investigating doping in sport is burgeoning, there is still a lack of proxy measures of doping behaviour that have undergone extensive psychometric testing. To address this issue, we modified a previously used measure of doping willingness in sport and tested aspects of validity and reliability across four studies. In Study 1, we provided support for the face and content validity of the items, and then found support for the factor structure of the scale in a sample of athletes (N = 205) using confirmatory factor analysis. In Study 2, we collected data from an independent sample of athletes (N = 236) to provide further evidence for the factor structure of the scale using confirmatory factor analysis as well as provided evidence for concurrent and discriminant validity. In Study 3, a further independent sample of athletes (N = 144) completed the scale and provided support for discriminant and predictive validity of the scale. In Study 4, we collected data from a further independent sample (N = 74) to provide support for the test-retest reliability, and stability of items. Lastly, a confirmatory factor analysis was conducted on the samples across Studies 3 and 4, and the composite sample across all four studies which provided further support for the factor structure of the final 8-item scale. Taken together, these findings provide psychometric support for the scale to be used to measure the willingness of athletes to use banned substances to help facilitate future research investigating doping in sport. This article is protected by copyright. All rights reserved.AIM To pilot test a home end-of-life and palliative care intervention for family caregivers and patients with rare advanced lung diseases and estimate effect-size for the power analysis in a future clinical trial. DESIGN This study uses a parallel randomized control trial. Families are randomly assigned to the intervention group or the control group in a 11 fashion. METHODS The study population includes patients with rare advanced lung diseases and their family caregivers who are involved in patients' home care. The control group receives standard care through their hospital or outpatient clinics. The intervention group receives standard care plus 2-weekly home end-of-life and palliative care coaching by experienced community nurses. Primary outcome is breathlessness measured by shortness of breath scale. check details Secondary outcomes are (1) caregivers' anxiety and depression measures; (2) the presence of patient's signed advance directives in the medical record or not; and (3) Helpfulness of intervention measured by self-report Helpfulness scale.